Scientists from the Dana-Farber Cancer Institute, principal teaching affiliate of Harvard Medical School, found new genetic markers that signal increased risk of developing the highly lethal disease. The discovery is based on a large DNA analysis of people with and without pancreatic cancer.
The markers are variations in the inherited DNA code at particular locations along chromosomes. Several of these variations in the DNA code were identified that influence an individual’s risk for pancreatic cancer.
… there is no population screening program for pancreatic cancer, which in 80% of cases is discovered when it’s too late for curative surgery..
The discovery of these new markers, along with four that were previously identified is important for several reasons, noted Brian Wolpin, MD, MPH, first author of the report published online by Nature Genetics. One is that further study of these DNA variants may help explain on the molecular level why some people are more or less susceptible to pancreatic cancer than the average person. A second is the potential to identify people at increased risk who then might be candidates to undergo MRI or ultrasound scanning to look for early, treatable pancreatic tumors.
Population screening
“Currently there is no population screening program for pancreatic cancer, which in 80% of cases is discovered when it’s too late to allow curative surgery ? the cancer has already spread,” Wolpin noted.
The only healthy individuals currently screened for pancreatic cancer are members of high risk families due to multiple family members with pancreatic cancer. “But the field has been struggling to find factors that can identify people at highest risk in the general population, when a strong family history is not present,” Wolpin explained.
Large DNA analysis
The study findings represent analyses of DNA from 7,683 patients with pancreatic cancer and 14,397 control patients without this cancer, all of European descent, from the United States, Europe, Canada, and Australia. The scientists used sequencing technology to examine more than 700,000 sites of the genome known to have single nucleotide polymorphisms (SNPs) ? differing versions of a single letter of DNA code. These variations can alter the expression of a gene or the content of its message, and the researchers looked for variants that were associated with the risk of having pancreatic cancer. Research of this type is called a genome-wide association study or GWAS.
Wolpin said the results confirmed the presence of four risk-associated SNPs that had been identified in a previous, smaller GWAS study. In addition, five new risk markers were discovered and a sixth that was of borderline statistical significance.
The risks linked to each SNP or marker were largely independent and additive, so that they may have utility in future attempts to identify individuals in the general population at higher risk for pancreatic cancer. The average lifetime risk of pancreatic cancer is 1.5%.
Risk stratification
The long-term goal is to create a “risk stratification tool” that could be used in primary care practice to identify individuals who should undergo screening for pancreatic cancer with tests such as ultrasound or MRI.
The project, known as PanScan III, was funded by numerous sources, including the National Cancer Institute of the National Institutes of Health and the Lustgarten Foundation.
For more information:
Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014 Aug 3. doi: 10.1038/ng.3052. [Article][PubMed]
Photo: Brian Wolpin from Dana-Farber led a large DNA analysis that has identified several new genetic markers that signal increased risk of developing pancreatic cancer. Photo Courtesy: Dana-Farber Cancer Institute.
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
